We were awarded the Chairman’s Choice Award in the GIC iX Program powered by the Stanford Center for Professional Development.
by Kim Lavine
"The journey of a founder is VERY hard."
You need to find inspiration, support and strength wherever you can. You need to believe in your mission with a sense of irrational optimism and indefatigable passion.
Sometimes along the way you get lucky and find a community of mentors who understands just how hard it is to try and change one small part of the world and offers you support. I found that community recently with the Stanford Center for Professional Development #GIC #GlobalInnovationCatalyst GICglobal
Alzheimer’s is one of the biggest, most persistent problems affecting humanity globally.
It will grow by 248% in the Americas, 345% in Africa, 226% in Asia and 90% in Europe in the next thirty years.
It will destroy lives, bankrupt families and push government healthcare budgets to the brink.
The global socioeconomic costs of Alzheimer’s will reach $2T by 2030, (more than cancer and heart disease) overwhelming health and social care systems—and that is just the tip of the iceberg.
Global pharmaceutical companies have failed to find an effective treatment for decades and, with the failure of two new drugs in the last year, there is nothing new in the pipeline for seven years.
We’re breaking the mold and defying ineffective legacy treatment protocols to courageously pioneer an early-intervention approach with our safe, simple and affordable MemorySPEX. Now as easy as putting on glasses, AD sufferers can reduce the plaque in the brain that causes memory loss up to 50%, in the comfort of their own home, without a prescription, in as little as 20 mins a
“One has very few opportunities in life to bring about meaningful global change. It begins by winning hearts and minds. To be able to save millions from needlessly suffering, to help end the heartbreak of those that love them, and to change outcomes for millions around the world, regardless of race, country or creed, is our mission at Hypersence.”
We’re creating the new future standard treatment for Alzheimer’s, but don’t just take my word for it, read what VentureNashville, one of the nation’s most respected healthcare investing sites, wrote about us recently https://www.venturenashville.com/startup-hypersence-seeks-2-5m-to-advance-memoryspex-its-platform-cms-2057. The editor Milt Capps did the most exhaustive due diligence on us, beginning with the premise that we were either in fact the real thing, or were too good to be true; according to Milt, we’re the real thing and we will change outcomes for millions.
There are few rare opportunities like ours to bring about meaningful change on a global scale. Will you join us?
